Novartis Faces Mounting ESG and Sustainability Risks That Could Weigh on Reputation, Financing, and Long-Term Value

Novartis AG (NVS) has disclosed a new risk, in the Environmental / Social category.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Novartis AG faces increasing risk from its ability to meet rapidly evolving social impact and sustainability expectations from regulators, investors, and broader stakeholders. Independent assessments of ESG performance are widely publicized and increasingly drive capital allocation, meaning weak performance could damage its reputation, talent attraction and retention, access to financing, and ultimately its share price. Large-scale societal issues such as social inequity, access to medicines, and climate change add complexity, as standards and regulatory requirements continue to shift and may at times conflict across jurisdictions. Moreover, ESG shortcomings or non-compliance by partners in its value chain, as well as potential litigation or regulatory actions, could materially and adversely impact Novartis AG’s operations, strategic goals, and long-term enterprise value.

The average NVS stock price target is $127.75, implying -16.45% downside potential.

To learn more about Novartis AG’s risk factors, click here.

Disclaimer & DisclosureReport an Issue